Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials

  
AMD
Novartis' Brolucizumab Met Primary Endpoints In nAMD patients In Ph III Studies Versus Aflibercept • Source: Shutterstock

More from Strategy

More from Business